losartan potassium/hydrochlorothiazide stada
stada arzneimittel ag - losartano kalio druska/hidrochlorotiazidas - plėvele dengtos tabletės - 100 mg/12,5 mg - losartan and diuretics
losartan potassium/hydrochlorothiazide stada
stada arzneimittel ag - losartano kalio druska/hidrochlorotiazidas - plėvele dengtos tabletės - 100 mg/25 mg - losartan and diuretics
amlodipine/valsartan/hydrochlorothiazide teva
teva b.v. - amlodipinas/valsartanas/hidrochlorotiazidas - plėvele dengtos tabletės - 10 mg/160 mg/12,5 mg - valsartan, amlodipine and hydrochlorothiazide
amlodipine/valsartan/hydrochlorothiazide teva
teva b.v. - amlodipinas/valsartanas/hidrochlorotiazidas - plėvele dengtos tabletės - 5 mg/160 mg/12,5 mg - valsartan, amlodipine and hydrochlorothiazide
sodium chloride fresenius
fresenius kabi polska sp.z.o.o. - natrio chloridas - koncentratas infuziniam tirpalui - 100 mg/ml - sodium chloride
potassium chloride braun
b.braun melsungen ag - kalio chloridas - koncentratas infuziniam tirpalui - 7,45 g/100 ml - potassium chloride
potassium chloride fresenius
fresenius kabi polska sp.z.o.o. - kalio chloridas - koncentratas infuziniam tirpalui - 100 mg/ml - potassium chloride
sodium chloride b.braun
b.braun melsungen ag - natrio chloridas - koncentratas infuziniam tirpalui - 9 g/1000 ml; 58,5 mg/ml - sodium chloride
kalio chloridas gsk
glaxosmithkline trading services limited - kalio chloridas - pailginto atpalaidavimo tabletės - 750 mg - potassium chloride
icandra (previously vildagliptin / metformin hydrochloride novartis)
novartis europharm limited - vildagliptin, metforminas hidrochloridas - cukrinis diabetas, 2 tipas - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ir 5. 1, jei yra duomenų apie skirtingus derinius).